Hannah Robinson, MD

Research Interests

My research interests are primarily focused on investigating new treatments for gastrointestinal cancers. This involves designing and conducting clinical trials and working with laboratory research colleagues to learn about why specific treatments are or are not effective.

Publications

• Robinson HR, Lakritz S, Pavlick DC, Davis SL, Lieu CH, Eule CJ, Graham LS, Spiess PE, Li R, Kamat AM, Grivas P, Jacob JM, Bratslavsky G, Basnet A, Wong KA, Lin DI, Necchi A, Ross JS, Lam ET. Squamous cell carcinoma of unknown primary (SCCUP): a genomic landscape study. ESMO Open. 2025 Jun;10(6):105312. PubMed PMID: 40499462
• Lentz RW, Lang J, Pitts TM, Blatchford P, Hu J, Jordan KR, Van Bokhoven A, Bagby SM, Dominguez ATA, Binns CA, Robinson HR, Balmaceda N, Baiyee E, Leal AD, Kim SS, Davis SL, Lieu CH, Wadlow RC, Spencer K, Scott AJ, Boland PM, Hochster HS, Messersmith WA. Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer. Cancer Res Commun. 2025 Nov 1;5(11):2039-2052. PubMed PMID: 41171165
• Lentz RW, Hu J, Robinson H, Balmaceda N, Baiyee E, Leal AD, Kim SS, Davis SL, Messersmith WA, Lieu CH. Real-World Analysis of Irinotecan With or Without Fluorouracil in the Second-Line Treatment of Metastatic Colorectal Cancer. J Natl Compr Canc Netw. 2025 Aug;23(8). PubMed PMID: 40763782
• Robinson HR, Pavlick D, Balmaceda NB, Ueberroth BE, Hayden A, Baiyee Toegel E, Lentz RW, Leal AD, Kim SS, Messersmith WA, Lieu CH, Ross JS, Davis S. TP53 Y220C mutations in pancreatic ductal adenocarcinoma (PDAC): A genomic landscape study. Journal of Clinical Oncology. 2025 January; 43(4_suppl).
• Balmaceda NB, Hu J, Alami V, Davis SL, Leal AD, Lentz RW, Robinson HR, Baiyee Toegel E, Lieu CH, Messersmith WA, Ueberroth BE, Hayden A, Kim SS. The association of antibiotic use and survival among patients receiving first line immunotherapy-based treatment for advanced gastroesophageal cancers. J Clin Oncol. 2025; 43 (Number 4_suppl): 349.
• Ueberroth BE, Robinson HR, Davis SL, Lieu CH, Balmaceda NB, Hayden A, Leal AD, Kim SS, Lentz RW, Messersmith WA, Baiyee Toegel E. Molecular and clinical profiling of gastroenteropancreatic (GEP) neuroendocrine tumors (NETs): An analysis of the Oncology Hannah R. Robinson, Curriculum Vitae Page 7 of 8 Research Information Exchange Network database. J Clin Oncol. 2025; 43 (Number 4_suppl): 669.
• Robinson HR, Messersmith WA, Lentz RW. HER2 Positive Metastatic Colorectal Cancer. Curr. Treat. Options in Oncol. 2024; 2024; 25: 585–604.
• Lentz RW, Friedrich T, Blatchford P, Jordan K, Pitts T, Robinson HR, Davis SL, Kim SS, Leal AD, Lee MR, Waring M, Martin A, Dominguez A, Bagby SM, Hartman SJ, Eckhardt SG, Messersmith WA, Lieu CH. A phase II study of potentiation of pembrolizumab with binimetinib and bevacizumab in refractory microsatellite stable colorectal cancer. Clinical Cancer Research. 2024 Sep 3;30(17):3768-3778.
• Robinson HR, Lakritz S, Pavlick DC, Davis S, Lieu C, Eule C, Graham LS, Spiess P, Li R, Kamat A, Grivas P, Jacob JM, Bratslavsky G, Basnet A, Wong K, Murugesan K, Lin DI, Neechi A, Ross JS, Lam ET. 1950P Squamous cell carcinoma of unknown primary (SCCUP): A genomic landscape study. Annals of Oncology. 2024 September; 35(Supplement 2):S1129-1130.
• Robinson HR, Hu J, Balmaceda N, Lentz RW, Baiyee E, Leal AD, Kim SS, Messersmith WA, Lieu CH, Davis SL. Real-World Use of Anti-EGFR Therapy in Colorectal Cancer. J Clin Oncol. 2024; 42 (Number 16_suppl):3552.
• Lentz RL, Blatchford PJ, Hu J, Pitts T, van Bokhoven A, Robinson HR, Balmaceda N, Baiyee ET, Leal AD, Kim SS, Davis SL, Lieu CH, Wadlow RC, Spencer KR, Scot AJ, Boland PM, Hochster HS, Messersmith WA. Results of a phase 2 study of evorpacept (E, ALX148), cetuximab (C), and pembrolizumab (P) in patients with refractory microsatellite stable metastatic colorectal cancer (MSS CRC). J Clin Oncol. 2024; 42 (Number 16_suppl):3530.
• Robinson HR, Hu J, Balmaceda N, Lentz RW, Baiyee E, Leal AD, Kim SS, Messersmith WA, Lieu CH, Davis SL. Disparities and trends in biomarker testing in metastatic colorectal cancer. J Clin Oncol. 2024; 42 (Number 3_suppl): 29.
• Robinson HR, Davis SL, Pavlick D, Murugesan K, Wong K, Lam ET, Ross JS, Lieu CH. Comprehensive genomic profiling of squamous cell carcinoma of unknown primary presenting with liver metastases. J Clin Oncol. 2024; 42 (Number 3_suppl): 755.
• Lakritz S, Robinson HR, Eule CJ, Graham L, Spiess PE, Li R, Kamat AM, Grivas P, Jacob JM, Bratslavsky G, Basnet A, Pavlick DC, Wong KA, Lin DI, Ross JS, Lam ET. Comprehensive Genomic Profiling of Squamous Cell Carcinoma of Unknown Primary (SCCUP) Presenting with Inguinal, Pelvic and Retroperitoneal Metastases. J Clin Oncol. 2024; 42 (Number 4_suppl): 7.
• Lentz RW, Hu J, Robinson HR, Balmaceda N, Baiyee E, Leal AD, Kim SS, Davis SL, Lieu CH, Messersmith WA. Real-world analysis of irinotecan (iri) with or without fluorouracil (5FU) in the 2nd line treatment of metastatic colorectal cancer (mCRC). J Clin Oncol. 2024; 42 (Number 3_suppl): 102.

Practice Locations

University of Colorado Cancer Center - Anschutz Medical Campus
1665 Aurora Ct
Aurora, CO 80045
720-848-0300

UCHealth Lone Tree Medical Center
9548 Park Meadows Drive
Lone Tree, CO 80124
720-848-2200

Specialty Information

Specialties

• Medical Oncology
• Hematology and Oncology

Conditions & Treatments

• Cancers
• Cancers - Gastroenterologic Cancer (Colon, Stomach, Esophageal, Liver)
• Blood / Lymphatic System
• Cancers - Cancer Medicine